RYTM Projected Dividend Yield
Rhythm Pharmaceuticals Inc ( NASDAQ : RYTM )Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE. IMCIVREE is a precision medicine approved by the FDA for chronic weight management in adults and children aged six and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiencies, or Bardet-Biedl syndrome (BBS). The company is also evaluating setmelanotide in Phase II and III trials for treating obesity linked to various MC4R pathway gene variants. 21 YEAR PERFORMANCE RESULTS |
RYTM Dividend History Detail RYTM Dividend News RYTM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |